Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barr; Stephen D. Smith; Mark J. Roschewski; Susan M. O’Brien; Jeff P. Sharman; Jason M. Melear; Priti Patel; Roser Calvo; Helen Yang; Stephen E. Spurgeon

doi:10.1080/10428194.2022.2043301

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Paul M. Barr, Stephen D. Smith, Mark J. Roschewski, Susan M. O’Brien, Jeff P. Sharman, Jason M. Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E. Spurgeon

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	1728-1732
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	63
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2022.2043301
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2022.2043301

Cite this

@article{310afdb9d3aa40e282d6b44cd700e479,

title = "Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma",

author = "Barr, {Paul M.} and Smith, {Stephen D.} and Roschewski, {Mark J.} and O{\textquoteright}Brien, {Susan M.} and Sharman, {Jeff P.} and Melear, {Jason M.} and Priti Patel and Roser Calvo and Helen Yang and Spurgeon, {Stephen E.}",

note = "Funding Information: This study was sponsored by Acerta Pharma, a member of the AstraZeneca group. Medical writing assistance was provided by Peloton Advantage, an OPEN Health company, and funded by Acerta Pharma.",

year = "2022",

doi = "10.1080/10428194.2022.2043301",

language = "English (US)",

volume = "63",

pages = "1728--1732",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

AU - Barr, Paul M.

AU - Smith, Stephen D.

AU - Roschewski, Mark J.

AU - O’Brien, Susan M.

AU - Sharman, Jeff P.

AU - Melear, Jason M.

AU - Patel, Priti

AU - Calvo, Roser

AU - Yang, Helen

AU - Spurgeon, Stephen E.

N1 - Funding Information: This study was sponsored by Acerta Pharma, a member of the AstraZeneca group. Medical writing assistance was provided by Peloton Advantage, an OPEN Health company, and funded by Acerta Pharma.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85125921760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125921760&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2043301

DO - 10.1080/10428194.2022.2043301

M3 - Letter

C2 - 35200084

AN - SCOPUS:85125921760

SN - 1042-8194

VL - 63

SP - 1728

EP - 1732

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this